 |
|
Scripps research scientists develop innovative dual action anthrax vaccine-antitoxin combination
October 05, 2007New compound could provide rapid treatment and long-term protection in a single injection
The immune response generated in rats by the new agent protects against lethal toxin exposure after only one injection, and is faster and stronger than any currently available vaccine.
The new study, led by Scripps Research scientists Anette Schneemann and Marianne Manchester, and Salk Institute Professor John A.T. Young, was published in the October 5 issue of the journal PLoS Pathogens (Volume 3, Issue 10).
"The new anti-anthrax agent that we developed is an important and potentially critical development for anyone who works with the bacterium or those who might be exposed to it in a bioterrorism attack," Schneemann said. "While other strategies are being pursued to develop improved anthrax vaccines, none of these offer the distinct advantage of combining the function of a vaccine with a potent antitoxin."
Concerns about anthrax-a potentially fatal disease caused by the spore-forming, gram-positive bacterium Bacillus anthracis-as a weapon of bioterrorism has prompted increased efforts to develop better antitoxins and vaccines. The current vaccine, which was developed in the 1950s, is safe and effective, but requires multiple injections followed by annual boosters. Current anthrax treatment involves antibiotics such as ciprofloxacin and doxycycline that attack the bacteria but provide no protection against the dangerous toxins secreted by the bacteria.
The new study introduces a highly effective dual-action compound that leapfrogs current efforts to develop a second-generation anthrax vaccine. In the research, the scientists created a "multivalent display," with several sites of attachment for recombinant protective antigen protein (PA), the primary component of the current anthrax vaccine, rather than only one. Virus-like particles coated with PA were found to produce a potent toxin-neutralizing antibody response that protected rats from the lethal anthrax toxin after only a single immunization.
The antitoxin strategy arose from the discovery of the anthrax toxin receptor, ANTXR2, in the Young lab. "The new anti-anthrax agent is based on a multivalent display of ANTXR2 on the surface of an insect virus," explains Schneemann. "Our approach was based on the assumption that a multivalent display of recombinant protective antigen protein would induce a far more potent immune response. That turned out to be correct."
Specifically, the new vaccine-antitoxin combination is based on the multivalent display (180 copies) of the PA-binding von Willebrand A (VWA) domain of the ANTXR2 cellular receptor on the Flock House virus. The chimeric virus-like particle platform, which produces protective immunity and has been shown to be safe, inhibited lethal toxin action in in vitro and in vivo models of anthrax infection.
In fact, rats survived exposure to the toxin four weeks after a single injection of the new double-acting agent. This result suggests an extremely rapid production of neutralizing antibodies without the use of an adjuvant, a secondary agent that helps stimulate the immune system and is often used to increase the vaccine response-key goals for the development of third-generation anthrax vaccines.
In addition to its use against anthrax, Schneemann notes that creating a multivalent platform may also have the potential to work against other infectious agents.
"One important reason for the success of this project is that it arose from the multidisciplinary and highly collaborative efforts of our team of microbiologists, structural biologists, and immunologists," said Manchester, who headed a National Institutes of Health (NIH)-funded program project grant that supported the work.
Scripps Research Institute
"The new anti-anthrax agent that we developed is an important and potentially critical development for anyone who works with the bacterium or those who might be exposed to it in a bioterrorism attack," Schneemann said. "While other strategies are being pursued to develop improved anthrax vaccines, none of these offer the distinct advantage of combining the function of a vaccine with a potent antitoxin."
Concerns about anthrax-a potentially fatal disease caused by the spore-forming, gram-positive bacterium Bacillus anthracis-as a weapon of bioterrorism has prompted increased efforts to develop better antitoxins and vaccines. The current vaccine, which was developed in the 1950s, is safe and effective, but requires multiple injections followed by annual boosters. Current anthrax treatment involves antibiotics such as ciprofloxacin and doxycycline that attack the bacteria but provide no protection against the dangerous toxins secreted by the bacteria.
The new study introduces a highly effective dual-action compound that leapfrogs current efforts to develop a second-generation anthrax vaccine. In the research, the scientists created a "multivalent display," with several sites of attachment for recombinant protective antigen protein (PA), the primary component of the current anthrax vaccine, rather than only one. Virus-like particles coated with PA were found to produce a potent toxin-neutralizing antibody response that protected rats from the lethal anthrax toxin after only a single immunization.
The antitoxin strategy arose from the discovery of the anthrax toxin receptor, ANTXR2, in the Young lab. "The new anti-anthrax agent is based on a multivalent display of ANTXR2 on the surface of an insect virus," explains Schneemann. "Our approach was based on the assumption that a multivalent display of recombinant protective antigen protein would induce a far more potent immune response. That turned out to be correct."
Specifically, the new vaccine-antitoxin combination is based on the multivalent display (180 copies) of the PA-binding von Willebrand A (VWA) domain of the ANTXR2 cellular receptor on the Flock House virus. The chimeric virus-like particle platform, which produces protective immunity and has been shown to be safe, inhibited lethal toxin action in in vitro and in vivo models of anthrax infection.
In fact, rats survived exposure to the toxin four weeks after a single injection of the new double-acting agent. This result suggests an extremely rapid production of neutralizing antibodies without the use of an adjuvant, a secondary agent that helps stimulate the immune system and is often used to increase the vaccine response-key goals for the development of third-generation anthrax vaccines.
In addition to its use against anthrax, Schneemann notes that creating a multivalent platform may also have the potential to work against other infectious agents.
"One important reason for the success of this project is that it arose from the multidisciplinary and highly collaborative efforts of our team of microbiologists, structural biologists, and immunologists," said Manchester, who headed a National Institutes of Health (NIH)-funded program project grant that supported the work.
Scripps Research Institute
Anthrax Current Events and Anthrax News RSSNature study demonstrates that bacterial clotting depends on clustering
Bacteria can directly cause human blood and plasma to clot-a process that was previously thought to have been lost during the course of vertebrate evolution, according to new research at the University of Chicago, National Institute of Allergy and Infectious Diseases, and Institut Pasteur in Paris. Their findings will be published online Nov. 2 in Nature Chemical Biology.
UCLA develops safer, more effective TB vaccine for HIV-positive people
UCLA scientists engineered a new tuberculosis (TB) vaccine specifically designed for HIV-positive people that was shown to be safer and more potent than the current TB vaccine in preclinical trials.
Green catalysts provide promise for cleaning toxins and pollutants
Tetra-Amido Macrocyclic Ligands (TAMLs) are environmentally friendly catalysts with a host of applications for reducing and cleaning up pollutants, and a prime example of "green chemistry." Carnegie Mellon University's Terry Collins, the catalyst's inventor, believes that the small-molecule catalysts have the potential to be even more effective than previously proven.
Nano vaccine for hepatitis B shows promise for third world
Chronic hepatitis B infects 400 million people worldwide, many of them children. Even with three effective vaccines available, hepatitis B remains a stubborn, unrelenting health problem, especially in Africa and other developing areas.
Francisella tularensis: Stopping a biological weapon
Scientists hope a vaccine is on the horizon for tularemia, a fatal disease caused by the pathogen Francisella tularensis, an organism of concern as a potential biological warfare agent. Until recently we knew very little about this bacterium.
Effective health messages may yield vaccine compliance among ER workers
Emergency room workers will be the first line of defense in the event of a disease pandemic and will be forced to deal with the chaos that inevitably comes with treating thousands of sick and dying. In order to protect themselves and allow them to care for the public, these first responders need to be fully prepared by getting available vaccines now.
Tests show LLNL detection instrument can monitor the air for all major terrorist threat substances
Security and law enforcement officials may some day have a new ally - a universal detection system that can monitor the air for virtually all of the major threat agents that could be used by terrorists.
New strategies against bird flu
The Spanish flu outbreak of 1918 killed between 30 and 50 million people. In the infected patients, the ultimate cause of death was acute respiratory distress syndrome (ARDS).
NIST, Army researchers pave the way for anthrax spore standards
Researchers from the National Institute of Standards and Technology (NIST) and the U.S. Army Dugway (Utah) Proving Ground have developed reliable methods based on DNA analysis to assess the concentration and viability of anthrax spores after prolonged storage.
Protein data bank archives 50,000th molecule structure
The Protein Data Bank (PDB) based at Rutgers, The State University of New Jersey, and the University of California-San Diego (UCSD) this month reached a significant milestone in its 37-year history. The 50,000th molecule structure was released into its archive, joining other structures vital to pharmacology, bioinformatics and education.
More Anthrax Current Events and Anthrax News Articles
 | Anthrax:: A History by Richard M. Swiderski Bacillus anthracis - anthrax - had largely faded from public consciousness until it resurfaced as a terrorist weapon in 2001. It was always with us, lurking in the soil and hosted by our livestock. Long before it was identified as a specific bacterium in the late 1800s, "anthrax" was a catchphrase for a variety of diseases and symptoms, from ancient biblical plagues to a painful carbuncle on... |
 | Bioterror: Anthrax, Influenza, and the Future of Public Health Security by R. William Johnstone This book uses the 2001 anthrax attacks as its point of departure for an analysis of the past, present, and future of America's preparedness to deal with major challenges to public health, including bioterrorism and pandemic flu. The study identified the strength and weaknesses of the system while making recommendations for improvements. This allows the U.S. to be better prepared if faced with a... |
 | The Anthrax Letters: A Medical Detective Story by Leonard A. Cole At 2:00am on October 2, 2001, Robert Stevens entered a hospital emergency room. Feverish, nauseated, and barely conscious, no one knew what was making him sick. It was the doctors and public health officials who solved this medical mystery. Stevens was the first fatal victim of bioterrorism in America. The events of September 11th and the anthrax attacks that followed only three weeks later were... |
 | Anthrax (Deadly Diseases and Epidemics) by Janet M. Decker Experts in the field of microbiology tell the great "detective stories" of how some of the world's best-known deadly disease-causing microbes were first isolated, identified, and studied. Readers learn how these deadly viruses and bacteria cause disease and what steps have been taken to eradicate them. Most commonly associated with animals such as livestock, the infectious disease anthrax... |
 | The Killer Strain: Anthrax and a Government Exposed by Marilyn W. Thompson A lethal germ is unleashed in the U.S. mail. A chain of letters spreads terror from Florida to Washington, D.C., from New York to Connecticut, from the halls of Congress to the assembly lines of the U.S. Postal Service. Five people die, and ten thousand more line up for antibiotics to protect against exposure. The government, already outsmarted by the terrorist hijackers of 9/11, leaves its... |
 | 2004 Complete Guide to Biological Weapons and Terrorism, Anthrax, Smallpox, Monkeypox, Ricin, Botulism, Brucellosis, Toxins, Plague, Q Fever, Tularemia, ... WMD, First Responder Two CD-ROM Set) by Department of Defense This up-to-date electronic book on CD-ROM contains the finest collection of authoritative federal documents available anywhere on the subject of biological weapons and bioterrorism - with information on every type of biological agent and attack, medical treatments, and much more - all fully indexed and completely searchable. There is material from the Dept. of Defense, Centers for Disease Control... |
 | Beyond Anthrax: The Weaponization of Infectious Diseases Beyond Anthrax: The Weaponization of Infection covers the gamut of potential biological threats related to biowarfare/bioterrorism as well as significant issues related to classical and new epidemics. Various aspects of the public health response to infections in both pre-event and post-event situations are also... |
 | Spores, Plagues and History: The Story of Anthrax by Chris Holmes Spores, Plagues and History is the tale of one of history's most deadly bacterium, which has been causing natural disease since the time of Moses and man-made illness since World War II. Beginning with a description of the U.S. anthrax bioterrorism attacks of 2001, the story goes back in time to the earlist hint of the disease, the 5th and 6th plagues of Moses. Several epidemics are then... |
 | Anthrax. Current Topics in Microbiology and Immunology, No. 271 Bacillus anthracis causes anthrax in all mammals, including humans. Depending upon the route of entry of B. anthracis spores, infection can result in cutaneous lesions, which are readily treatable with antibiotics, or systemic lethal disease, which is nearly always fatal. The continuing worldwide incidence of anthrax in animal populations, the risk of human infection associated with animal... |
 | Analyzing The Anthrax Attacks by Edward G. Lake How could so many people be so wrong about the anthrax attacks of 2001? This book explains how. Using published scientific data confirmed via one-on-one discussions with America's top anthrax experts, this book shows that simple laboratory mistakes made in the first days of the investigation were leaked to the media before they could be corrected and led to wild conspiracy theories which... |
| © 2008 BrightSurf.com |